Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed Papers
Pharmaceutical Approval Update.
Biochemical, cell biological, pathological, and therapeutic aspects of Krabbe's disease.
No association of multiple sclerosis activity and progression with EBV or tobacco use in BENEFIT.
Modeling the Chronic Loss of Optic Nerve Axons and the Effects on the Retinal Nerve Fiber Layer Structure in Primary Disorder of Myelin.
Simulations on the influence of myelin water in diffusion-weighted imaging.
Epidermal growth factor preserves myelin and promotes astrogliosis after intraventricular hemorrhage.
Commentary on painful tonic spasms and brainstem involvement in a patient with neuromyelitis optica spectrum disorder.
Epigenomic Regulation of Schwann Cell Reprogramming in Peripheral Nerve Injury.
Depressive Symptoms Correlate with Disability and Disease Course in Multiple Sclerosis Patients: An Italian Multi-Center Study Using the Beck Depression Inventory.
Altered T cell phenotypes associated with clinical relapse of multiple sclerosis patients receiving fingolimod therapy.
[Progressive multifocal leukoencephalopathy].
Patients' satisfaction with and views about treatment with disease-modifying drugs in multiple sclerosis.
Plasma complement biomarkers distinguish multiple sclerosis and neuromyelitis optica spectrum disorder.
Loss of Myelin Basic Protein Function Triggers Myelin Breakdown in Models of Demyelinating Diseases.
The impact of adjusted work conditions and disease-modifying drugs on work ability in multiple sclerosis.
Longitudinally extensive transverse myelitis: A retrospective analysis of sixty-four patients at tertiary care center of North-West India.
Vitamin D and Systemic Lupus Erythematosus: Myth or Reality?
2'-5' oligoadenylate synthetase-like 1 (OASL1) deficiency suppresses central nervous system damage in a murine MOG-induced multiple sclerosis model.
[The correlation factor analysis for conversion of clinically isolated syndrome to multiple sclerosis and neuromyelitis optica].
Neurologic syndrome associated with homozygous mutation at MAG sialic acid binding site.
Relationship between the corpus callosum and neurocognitive disabilities in children with NF-1: diffusion tensor imaging features.
Diffusion tensor microscopy data (15.6 μm in-plane) of white matter tracts in the human, pig, and rat spinal cord with corresponding tissue histology.
Cellular mechanisms of adaptive myelination: bridging the gap between animal studies and human cognition.
Iranian consensus on use of vitamin D in patients with multiple sclerosis.
Cognitive motor interference in multiple sclerosis: Insights from a systematic, quantitative review.
Pages
« first
‹ previous
…
783
784
785
786
787
788
789
790
791
…
next ›
last »